Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation
Karly C. Sourris(Baker Heart and Diabetes Institute), Melinda T. Coughlan(Baker Heart and Diabetes Institute), Assam El‐Osta(University of Copenhagen), Yangsong Xu(Baker Heart and Diabetes Institute), Josephine M. Forbes(Translational Research Institute), Carlos J. Rosado(Diabetes Australia), Karin Jandeleit‐Dahm(Deutsches Diabetes-Zentrum e.V.), Annas Al‐Sharea(Baker Heart and Diabetes Institute), Muthukumar Mohan(Monash Alfred Psychiatry Research centre), Phillip Kantharidis(Diabetes Australia), Scott Maxwell(Baker Heart and Diabetes Institute), Claus Haase(Novo Nordisk (Denmark)), Daniel J. Drucker(University of Toronto), Andrew Advani(St. Michael's Hospital), Mark E. Cooper(Australian Regenerative Medicine Institute), Andrew Murphy(Baker Heart and Diabetes Institute), Brooke E. Harcourt(Albert Einstein College of Medicine), Anil Karihaloo(Novo Nordisk (United States)), Lotte Bjerre Knudsen(Novo Nordisk (Denmark)), Yi Ding(Baker Heart and Diabetes Institute), Sally A. Penfold(Albert Einstein College of Medicine), Simon Crawford(Monash University), Daniel B. Timmermann(Novo Nordisk (Denmark)), Georg Ramm(Garvan Institute of Medical Research)
Cited by 121
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Diabetic kidney disease
|Nature Reviews Disease Primers|2015|1.2k
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
|Journal of Clinical Investigation|2014|913
The Discovery and Development of Liraglutide and Semaglutide
|Frontiers in Endocrinology|2019|890
Semaglutide lowers body weight in rodents via distributed neural pathways
|JCI Insight|2020|664